PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL - DuRIANS (Durvalumab Revlimid In Aggressive NHL Subtypes)
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma; Plasmablastic lymphoma
- Focus Therapeutic Use
- Acronyms DuRIANS
- 11 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to FDA hold for combination studies using Imids and PD1/PDL1 compounds
- 14 Jul 2017 New trial record